Publicaciones

Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir).

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.

Differential restrictions on antigenic variation among antigenic sites of foot-and-mouth disease virus in the absence of antibody selection.

Quasispecies, fitness jumps, and the emergence of new viruses

Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants.

Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.

Evolution subverting essentiality: dispensability of the cell attachment Arg-Gly-Asp motif in multiply passaged foot-and-mouth disease virus.

Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.

Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.

[Bronchogenic carcinoma in patients with human immunodeficiency virus infection].